Acetylcysteine
Acetadote, Acetylcysteine (acetylcysteine) is a small molecule pharmaceutical. Acetylcysteine was first approved as Mucomyst on 1982-01-01. It is used to treat amyloidosis, bronchiectasis, bronchitis, cystic fibrosis, and pneumonia amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Acetadote, Acetylcysteine (discontinued: Acetylcysteine, Cetylev, Mucomyst, Mucosil)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acetylcysteine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ACETADOTE | Cumberland Pharmaceuticals | N-021539 RX | 2004-01-23 | 1 products, RLD, RS |
Show 2 discontinued
Acetylcysteine
+
Isoproterenol hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MUCOMYST W/ ISOPROTERENOL | Mead Johnson Nutrition | N-017366 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acetadote | New Drug Application | 2025-04-30 |
| acetylcysteine | ANDA | 2025-08-26 |
| antiseptic cleansing wipe(0.9% nacl) | C200263 | 2025-04-28 |
| disinfectant(naclo) | unapproved drug other | 2020-04-18 |
| esika natural care concha de nacar and rosa mosqueta facial fps 15 | OTC monograph not final | 2014-02-19 |
| nacellate solution 0.9% - 1000ml | New Drug Application | 2022-02-23 |
| nacellate solution 0.9% - 100ml | New Drug Application | 2022-02-23 |
| nacellate solution 0.9% - 250ml | New Drug Application | 2022-02-23 |
| nacellate solution 0.9% - 500ml | New Drug Application | 2022-02-23 |
| nasocalm | C200263 | 2025-03-28 |
Show 4 more
Indications
FDA
EMA
Show 6 more
Agency Specific
FDA
EMA
No data
Patent Expiration
ATC Codes
R: Respiratory system drugs
— R05: Cough and cold preparations
— R05C: Expectorants, excl. combinations with cough suppressants
— R05CB: Mucolytics
— R05CB01: Acetylcysteine
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01X: Other ophthalmologicals in atc
— S01XA: Other ophthalmologicals in atc
— S01XA08: Acetylcysteine
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AB: Antidotes
— V03AB23: Acetylcysteine
HCPCS
Code | Description |
|---|---|
| J0132 | Injection, acetylcysteine, 100 mg |
| J7604 | Acetylcysteine, inhalation solution, compounded product, administered through dme, unit dose form, per gram |
| J7608 | Acetylcysteine, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per gram |
Clinical
Clinical Trials
917 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | 4 | 10 | 13 | 9 | 10 | 40 |
| Covid-19 | D000086382 | — | U07.1 | 10 | 10 | 4 | 1 | 4 | 26 |
| Syndrome | D013577 | — | — | 3 | 9 | — | 4 | 6 | 20 |
| Oxidative stress | D018384 | EFO_1001905 | — | 4 | 5 | 3 | 2 | 7 | 20 |
| Renal insufficiency | D051437 | — | N19 | 2 | 7 | 4 | 4 | 5 | 20 |
| Inflammation | D007249 | MP_0001845 | — | 3 | 4 | 2 | 2 | 7 | 17 |
| Acute kidney injury | D058186 | — | N17 | — | 3 | 5 | 4 | 6 | 17 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 3 | 8 | 6 | 17 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | 3 | 7 | 1 | 4 | 15 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 3 | 9 | 1 | 2 | 1 | 15 |
Show 145 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 7 | 8 | 1 | — | 53 | 68 |
| Healthy volunteers/patients | — | — | — | 12 | — | 1 | — | 5 | 18 |
| Neoplasms | D009369 | — | C80 | 7 | 10 | 1 | — | 1 | 15 |
| Fibrosis | D005355 | — | — | 3 | 7 | 3 | — | 1 | 11 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 3 | 4 | 1 | — | 3 | 10 |
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | 2 | 4 | 3 | — | 4 | 10 |
| Hepatitis | D006505 | — | K75.9 | — | 3 | 4 | — | 5 | 10 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 3 | 1 | — | 6 | 10 |
| Pulmonary fibrosis | D011658 | — | J84.10 | 3 | 5 | 3 | — | 1 | 9 |
| Rhinitis | D012220 | EFO_0008521 | J31 | 2 | 3 | 2 | — | 4 | 9 |
Show 94 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Triple negative breast neoplasms | D064726 | — | — | 1 | 5 | — | — | 5 | 11 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 2 | 4 | — | — | 5 | 10 |
| Carcinoma | D002277 | — | C80.0 | 1 | 3 | — | — | 4 | 8 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 3 | 3 | — | — | 3 | 8 |
| Invasive hydatidiform mole | D002820 | — | D39.2 | — | 3 | — | — | 4 | 7 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 3 | 3 | — | — | 2 | 7 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | 4 | — | — | 2 | 7 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | 1 | — | — | 5 | 7 |
| Compulsive personality disorder | D003193 | — | F60.5 | — | 3 | — | — | 3 | 6 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 2 | 2 | — | — | 2 | 5 |
Show 203 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 2 | — | — | — | 3 | 5 |
| Pruritus | D011537 | — | L29 | 1 | — | — | — | 3 | 4 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | — | — | — | 1 | 3 |
| Crohn disease | D003424 | EFO_0000384 | K50 | 1 | — | — | — | 1 | 2 |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | 1 | — | — | — | 1 | 2 |
| Thalassemia | D013789 | EFO_1001996 | D56 | 1 | — | — | — | 1 | 2 |
| Glaucoma | D005901 | EFO_0000516 | H40 | 1 | — | — | — | 1 | 2 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | 1 | — | — | — | 1 | 2 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | 1 | — | — | — | 1 | 2 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | 2 | — | — | — | — | 2 |
Show 40 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | — | — | — | 5 | 5 |
| Apnea | D001049 | — | R06.81 | — | — | — | — | 5 | 5 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | — | — | 4 | 4 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | — | — | — | 4 | 4 |
| Hyperhomocysteinemia | D020138 | — | — | — | — | — | — | 3 | 3 |
| Vascular dementia | D015140 | — | F01 | — | — | — | — | 2 | 2 |
| Brain concussion | D001924 | — | S06.0 | — | — | — | — | 2 | 2 |
| Memory disorders | D008569 | — | — | — | — | — | — | 2 | 2 |
| Amnesia | D000647 | EFO_1001454 | F44.0 | — | — | — | — | 2 | 2 |
| Humans | D006801 | — | STY/T016 | — | — | — | — | 2 | 2 |
Show 129 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Acetylcysteine |
| INN | acetylcysteine |
| Description | N-acetyl-L-cysteine is an N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine. It has a role as an antiinfective agent, an antioxidant, an antiviral drug, an antidote to paracetamol poisoning, a vulnerary, a mucolytic, a human metabolite, a radical scavenger, a ferroptosis inhibitor and a geroprotector. It is a L-cysteine derivative, an acetylcysteine and a N-acetyl-L-amino acid. It is a conjugate acid of a N-acetyl-L-cysteinate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)N[C@@H](CS)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 616-91-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL600 |
| ChEBI ID | 28939 |
| PubChem CID | 12035 |
| DrugBank | DB06151 |
| UNII ID | WYQ7N0BPYC (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Acetadote – Cumberland Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Acetylcysteine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 31,272 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
204,333 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use